Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018.
USL2611 already granted orphan drug and fast track designation by the United States Food and Drug Administration, due to the high unmet need for patients and caregivers.
Nasal administration could provide significant value to patients who currently have limited treatment options.
Acquisition of USL261 complements UCB’s already successful anti-epilepsy drug portfolio, enhancing the company’s position as a global leader in epilepsy.
BRUSSELS, Belgium I April 20, 2018 I UCB today announced an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261)1, an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.
USL2612 is a novel investigational midazolam formulation, which has been specifically designed for intranasal delivery without active inhalation. It has been granted orphan drug designation and fast track designation by the United States Food and Drug Administration (FDA), reflecting the significant unmet need which currently exists for ARS rescue treatment.
Rectally administered benzodiazepines, such as diazepam, are commonly prescribed for the treatment of ARS. However, whilst this has traditionally provided patients and caregivers with a much-needed treatment option, this route of administration may be cumbersome and problematic in social settings. A treatment administered nasally would provide important additional treatment options.
USL261 has demonstrated strong results in a significant Phase 3 clinical trial3 program and the intention is to file USL261 as a New Drug Application (NDA) in the course of 2018
“There is a real and pressing need for effective and convenient rescue treatments in ARS that rapidly end ongoing seizures as well as those that prevent seizure reoccurrence,” explained Jean-Christophe Tellier, CEO of UCB. “Midazolam Nasal Spray has delivered strong Phase 3 results; our acquisition of this program, when approved, will expand and diversify the treatment choices we are able to provide to the epilepsy community, complementing our strong internal portfolio and building on our extensive knowledge, passion and expertise in the field of epilepsy.”
UCB estimates that more than 150,000 people with refractory epilepsy also experience ARS.4
These types of seizures pose multiple risks to patients, which include repeated emergency room related hospitalizations each year and possible evolution into status epilepticus, a potentially life-threatening seizure state.
“Rescue treatment options for acute repetitive seizures have historically been very limited. As a global leader in epilepsy, with a pioneering commitment to improving patient value, UCB was the natural choice to progress the development journey of midazolam nasal spray” said Bill Pullman, Chief Scientific Officer and President, Proximagen. “In making this important new medicine available, following approval, UCB will be delivering an effective rescue treatment option for patients and caregivers living with ARS. I’d like to take this opportunity to thank our investigators, along with the teams at Upsher-Smith and Proximagen who have brought us to this major milestone,” said Mark Evenstad, Executive Chairman of ACOVA, Inc., parent company of Proximagen
UCB believes USL2615 has the potential to complement its already successful portfolio of epilepsy medicines, significantly improving its ability to provide additional treatment choice and value to millions of people living with poorly controlled seizures.
Under the terms of the agreement, UCB will make an upfront cash payment of $150 million. In addition, Proximagen is eligible to receive contingent payments of up to $220 million based on certain regulatory approval and sales-based milestones.
The transaction is expected to close in the second quarter of 2018, subject to the satisfaction of customary closing conditions including the satisfaction of the notification and waiting period requirements of the Hart-Scott-Rodino Act
Lazard is acting as financial advisor to UCB. Covington & Burling LLP is acting as legal counsel to UCB. BMO Capital Markets Corp. is acting as financial advisor to Proximagen. Ballard Spahr LLP is acting as legal counsel to Proximagen
About UCB in Epilepsy
UCB has a rich heritage in epilepsy with over 20 years of experience in the research and development of antiepileptic drugs. As a company with a long-term commitment to epilepsy research, our goal is to address unmet medical needs. Our scientists are proud to contribute to advances in the understanding of epilepsy and its treatment. We partner and create super-networks with world-leading scientists and clinicians in academic institutions, pharmaceutical companies and other organizations who share our goals. At UCB, we are inspired by patients, and driven by science in our commitment to support patients with epilepsy.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With around 7,500 people operating in 40 countries, the company generated revenue of €4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
About Proximagen
Proximagen LLC, a member of the ACOVA family of companies located in Plymouth MN (USA), specializes in the development of novel small molecule therapeutics in the areas of CNS, pain and inflammation. As part of the Upsher-Smith Laboratories family of companies prior to the sale of its generics business in 2017, Proximagen has a long heritage in drug development.
USL261 has not been submitted to or approved by the FDA. These statements solely reflect the opinions of the authors.
Id.
This statement has not been submitted to the FDA and solely reflects the opinions of the authors.
Haut SR. Current Opinion in Neurology 2015, 28:143–150
USL261 has not been submitted to or approved by the FDA. These statements solely reflect the opinions of the authors.
SOURCE: UCB
Post Views: 13
Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018.
USL2611 already granted orphan drug and fast track designation by the United States Food and Drug Administration, due to the high unmet need for patients and caregivers.
Nasal administration could provide significant value to patients who currently have limited treatment options.
Acquisition of USL261 complements UCB’s already successful anti-epilepsy drug portfolio, enhancing the company’s position as a global leader in epilepsy.
BRUSSELS, Belgium I April 20, 2018 I UCB today announced an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261)1, an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.
USL2612 is a novel investigational midazolam formulation, which has been specifically designed for intranasal delivery without active inhalation. It has been granted orphan drug designation and fast track designation by the United States Food and Drug Administration (FDA), reflecting the significant unmet need which currently exists for ARS rescue treatment.
Rectally administered benzodiazepines, such as diazepam, are commonly prescribed for the treatment of ARS. However, whilst this has traditionally provided patients and caregivers with a much-needed treatment option, this route of administration may be cumbersome and problematic in social settings. A treatment administered nasally would provide important additional treatment options.
USL261 has demonstrated strong results in a significant Phase 3 clinical trial3 program and the intention is to file USL261 as a New Drug Application (NDA) in the course of 2018
“There is a real and pressing need for effective and convenient rescue treatments in ARS that rapidly end ongoing seizures as well as those that prevent seizure reoccurrence,” explained Jean-Christophe Tellier, CEO of UCB. “Midazolam Nasal Spray has delivered strong Phase 3 results; our acquisition of this program, when approved, will expand and diversify the treatment choices we are able to provide to the epilepsy community, complementing our strong internal portfolio and building on our extensive knowledge, passion and expertise in the field of epilepsy.”
UCB estimates that more than 150,000 people with refractory epilepsy also experience ARS.4
These types of seizures pose multiple risks to patients, which include repeated emergency room related hospitalizations each year and possible evolution into status epilepticus, a potentially life-threatening seizure state.
“Rescue treatment options for acute repetitive seizures have historically been very limited. As a global leader in epilepsy, with a pioneering commitment to improving patient value, UCB was the natural choice to progress the development journey of midazolam nasal spray” said Bill Pullman, Chief Scientific Officer and President, Proximagen. “In making this important new medicine available, following approval, UCB will be delivering an effective rescue treatment option for patients and caregivers living with ARS. I’d like to take this opportunity to thank our investigators, along with the teams at Upsher-Smith and Proximagen who have brought us to this major milestone,” said Mark Evenstad, Executive Chairman of ACOVA, Inc., parent company of Proximagen
UCB believes USL2615 has the potential to complement its already successful portfolio of epilepsy medicines, significantly improving its ability to provide additional treatment choice and value to millions of people living with poorly controlled seizures.
Under the terms of the agreement, UCB will make an upfront cash payment of $150 million. In addition, Proximagen is eligible to receive contingent payments of up to $220 million based on certain regulatory approval and sales-based milestones.
The transaction is expected to close in the second quarter of 2018, subject to the satisfaction of customary closing conditions including the satisfaction of the notification and waiting period requirements of the Hart-Scott-Rodino Act
Lazard is acting as financial advisor to UCB. Covington & Burling LLP is acting as legal counsel to UCB. BMO Capital Markets Corp. is acting as financial advisor to Proximagen. Ballard Spahr LLP is acting as legal counsel to Proximagen
About UCB in Epilepsy
UCB has a rich heritage in epilepsy with over 20 years of experience in the research and development of antiepileptic drugs. As a company with a long-term commitment to epilepsy research, our goal is to address unmet medical needs. Our scientists are proud to contribute to advances in the understanding of epilepsy and its treatment. We partner and create super-networks with world-leading scientists and clinicians in academic institutions, pharmaceutical companies and other organizations who share our goals. At UCB, we are inspired by patients, and driven by science in our commitment to support patients with epilepsy.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With around 7,500 people operating in 40 countries, the company generated revenue of €4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
About Proximagen
Proximagen LLC, a member of the ACOVA family of companies located in Plymouth MN (USA), specializes in the development of novel small molecule therapeutics in the areas of CNS, pain and inflammation. As part of the Upsher-Smith Laboratories family of companies prior to the sale of its generics business in 2017, Proximagen has a long heritage in drug development.
USL261 has not been submitted to or approved by the FDA. These statements solely reflect the opinions of the authors.
Id.
This statement has not been submitted to the FDA and solely reflects the opinions of the authors.
Haut SR. Current Opinion in Neurology 2015, 28:143–150
USL261 has not been submitted to or approved by the FDA. These statements solely reflect the opinions of the authors.
SOURCE: UCB
Post Views: 13
